Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 10/20 | 0.54 |
| ▸ | CDK2 | P24941 | 10/20 | 0.54 |
| ▸ | CDK12 | Q9NYV4 | 9/20 | 0.54 |
| ▸ | CCNK | O75909 | 6/20 | 0.54 |
| ▸ | CDK7 | P50613 | 5/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.54 |
| ▸ | CCNH | P51946 | 3/20 | 0.54 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.54 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.54 |
| ▸ | CDK1 | P06493 | 6/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.43 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22388813 | 0.89 | CDK2 (0.48) | CDK9CDK2CDK12CCNKCDK7 | |
| SCHEMBL20549443 | 0.85 | CDK9 (0.67) | CDK9CDK2CDK12CCNKCDK7 | |
| SCHEMBL18122680 | 0.85 | CDK9 (0.67) | CDK9CDK2CDK12CCNKCDK7 | |
| SCHEMBL18313332 | 0.85 | CDK9 (0.51) | CDK9CDK2CDK12CCNKCDK7 | |
| SCHEMBL18113944 | 0.80 | CDK9 (0.77) | CDK9CDK2CDK12CCNKCDK7 | |
| SCHEMBL18113943 | 0.80 | CDK9 (0.77) | CDK9CDK2CDK12CCNKCDK7 | |
| SCHEMBL18113966 | 0.79 | CDK2 (0.45) | CDK9CDK2CDK12CCNKCDK7 | |
| SCHEMBL18313574 | 0.78 | CDK2 (0.52) | CDK9CDK2CDK12CCNE1CDK1 | |
| SCHEMBL20549444 | 0.78 | CDK9 (0.70) | CDK9CDK2CDK12CCNKCDK7 | |
| SCHEMBL20549440 | 0.78 | CDK9 (0.70) | CDK9CDK2CDK12CCNKCDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| EP-3273966-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA FARBER CANCER INST INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11325910-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| WO-2016201370-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325910-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | CDK9 21/4885CDK2 6/4885CDK12 4/4885 |
| US-10550121-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | CDK9 21/4885CDK2 6/4885CDK12 4/4885 |
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK9 21/4885CDK2 6/4885CDK12 4/4885 |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | CDK9 21/4885CDK2 6/4885CDK12 4/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | CDK9 89/4885CDK2 63/4885CDK12 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.